Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab post-operatively.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
Non-thermal ablation of tumor
University of Louisville
Louisville, Kentucky, United States
RECRUITINGSafety and Tolerability of Combination Irreversible Electroporation and Nivolumab Treatment
Adverse events and Serious adverse events will be collected
Time frame: Baseline thru 100 days after receiving last dose
Progression Free Survival
CT scans will be reviewed
Time frame: Every three months for 4 years.
Overall Survival
CT scans will be reviewed
Time frame: Every three months for 4 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.